Enlivex says FDA grants RMAT designation for Allocetra in age-related knee osteoarthritis - ENLV News | RalliesEnlivex says FDA grants RMAT designation for Allocetra in age-related knee osteoarthritis
E
ENLV• FDA grants RMAT designation for Allocetra
- FDA granted RMAT designation to Allocetra for age-related symptomatic knee osteoarthritis in patients aged 64 and older.
- The designation supports an expedited development path, including potential eligibility for accelerated approval or priority review.
- Enlivex said its Phase IIb trial targets 182 patients in the US and EU, with top-line data expected by the end of Q2 2027.
FRMI
•
